Raymond James Financial
IMVT icon

Raymond James Financial’s Immunovant IMVT Stock Holding History

Raymond James Financial’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$205K Buy
+8,257
New +$214K ﹤0.01% 4876
2025
Q3 		– Sell
-300
Closed -$4.8K – 5807
2025
Q2 		$4.8K Sell
300
-59,374
-99% -$898K ﹤0.01% 6184
2025
Q1 		$1.02M Buy
59,674
+39,292
+193% +$822K ﹤0.01% 3474
2024
Q4 		$505K Buy
+20,382
New +$578K ﹤0.01% 3901

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Raymond James Financial's IMVT Position: Q1 2026 in Review

Raymond James Financial opened a new position in Immunovant (IMVT) in Q1 2026: 8,257 shares worth $205K. The stake represents ﹤0.01% of the portfolio and ranks #4876 among its holdings. This is a return to the name: Raymond James Financial previously reported a position in IMVT as recently as Q2 2025.

Raymond James Financial first reported a position in IMVT in Q4 2024 and has held it in 4 quarters since. The position peaked at $1.02M in Q1 2025. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Raymond James Financial held 8,257 shares of Immunovant worth $205K as of Q1 2026.
  • Immunovant was a new Raymond James Financial position in Q1 2026.
  • Immunovant made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #4876 holding.
  • Raymond James Financial first reported a position in Immunovant in Q4 2024 and has held it in 4 quarters since.
  • Raymond James Financial's Immunovant position peaked at $1.02M in Q1 2025.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.